XML 75 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition Business Combination Details- Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2017
May 31, 2016
Dec. 31, 2017
Sep. 30, 2016
Jun. 30, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 06, 2017
Oct. 03, 2017
Sep. 30, 2017
Business Acquisition [Line Items]                      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                   $ 8,950,000,000  
Business Combination, Consideration Transferred $ 11,155,000,000                    
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 75,000,000                    
Allocated Share-based Compensation Expense           $ 649,000,000 $ 380,000,000 $ 382,000,000      
Fair Value Inputs, Discount Rate           9.50%          
Gross Carrying Amount     $ 18,154,000,000     $ 18,154,000,000 11,863,000,000        
Goodwill Acquired From Business Combination 2,987,000,000                    
Operating Income (Loss)           14,124,000,000 17,633,000,000 22,193,000,000      
Research and development expenses           $ 3,734,000,000 $ 5,098,000,000 $ 3,014,000,000      
Payments to Outstanding Common Stockholders [Member]                      
Business Acquisition [Line Items]                      
Payments to Acquire Businesses, Gross 10,420,000,000                    
Payments to Vested Equity Award Holders [Member]                      
Business Acquisition [Line Items]                      
Payments to Acquire Businesses, Gross 645,000,000                    
Payments to Warrant Holders [Member]                      
Business Acquisition [Line Items]                      
Payments to Acquire Businesses, Gross 15,000,000                    
Share Based Compensation Expense [Member]                      
Business Acquisition [Line Items]                      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned                   $ 733,000,000  
Kite Pharma, Inc [Member]                      
Business Acquisition [Line Items]                      
Business Acquisition, Share Price                   $ 180  
Allocated Share-based Compensation Expense     238,000,000                
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost     209,000,000                
Operating Income (Loss)     675,000,000                
Acquisition Costs, Period Cost     431,000,000                
Share-based Compensation     290,000,000                
Amortization of Intangible Assets     $ 73,000,000                
Business Acquisition, Transaction Costs                   $ 48,000,000  
Ownership Cell Design Labs, Inc.     12.20%     12.20%          
Research and development expenses     $ 222,000,000                
2017 Senior Unsecured Notes [Member]                      
Business Acquisition [Line Items]                      
Debt Instrument, Face Amount                     $ 3,000,000,000.0
Term Loan Facilities [Member]                      
Business Acquisition [Line Items]                      
Line of Credit Facility, Maximum Borrowing Capacity $ 6,000,000,000                    
Intangible Asset - axicabtagene ciloleucel (DLBCL) [Member]                      
Business Acquisition [Line Items]                      
Gross Carrying Amount     6,200,000,000     $ 6,200,000,000          
Finite-Lived Intangible Asset, Useful Life           18 years          
Intangible Asset - Daiichi Sankyo [Member]                      
Business Acquisition [Line Items]                      
Gross Carrying Amount     91,000,000     $ 91,000,000          
Finite-Lived Intangible Asset, Useful Life           14 years          
Acquisition-related Costs [Member]                      
Business Acquisition [Line Items]                      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost           $ 223,000,000          
Proforma Adjustments Acquisition Related Transacton Expenses           139,000,000          
Cell Design Labs, Inc. [Member]                      
Business Acquisition [Line Items]                      
Business Combination, Consideration Transferred     $ 150,000,000                
Regulatory Milestone-based Payments, Maximum           322,000,000          
Carrying Value of Equity Interest Owned Prior to Acquisition                 $ 30,000,000    
Acquired IPR&D CDL           $ 172,000,000          
Nimbus Apollo, Inc. [Member]                      
Business Acquisition [Line Items]                      
Research and development expenses   $ 400,000,000   $ 200,000,000 $ 400,000,000            
Regulatory Milestone-based Payments, Maximum   $ 800,000,000